PYROXD2

Across TCGA pan-cancer cohorts, PYROXD2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PYROXD2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PYROXD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PYROXD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where PYROXD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.934	0.689	.009	28	view →
LSCC	DFS	Tertile	All	0.513	0.793	.006	25	view →
PDAC	OS	Median	All	0.368	0.732	.001	25	view →
UCEC	OS	Median	III,IV	0.494	1.000	.016	24	view →
HNSC	DFS	Tertile	III,IV	0.412	0.771	.001	13	view →
GBM	OS	Median	All	0.285	0.513	.024	4	view →
LUAD	DFS	Quartile	III,IV	0.281	0.879	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PYROXD2–CCRCC (OS)

Open the CCRCC breakdown →